312 related articles for article (PubMed ID: 23197495)
1. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
Chew V; Tow C; Huang C; Bard-Chapeau E; Copeland NG; Jenkins NA; Weber A; Lim KH; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
J Natl Cancer Inst; 2012 Dec; 104(23):1796-807. PubMed ID: 23197495
[TBL] [Abstract][Full Text] [Related]
2. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.
Chew V; Chen J; Lee D; Loh E; Lee J; Lim KH; Weber A; Slankamenac K; Poon RT; Yang H; Ooi LL; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
Gut; 2012 Mar; 61(3):427-38. PubMed ID: 21930732
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
Bonnin M; Fares N; Testoni B; Estornes Y; Weber K; Vanbervliet B; Lefrançois L; Garcia A; Kfoury A; Pez F; Coste I; Saintigny P; Viari A; Lang K; Guey B; Hervieu V; Bancel B; Bartoch B; Durantel D; Renno T; Merle P; Lebecque S
J Hepatol; 2019 Oct; 71(4):763-772. PubMed ID: 31220470
[TBL] [Abstract][Full Text] [Related]
4. The miR-561-5p/CX
Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
[TBL] [Abstract][Full Text] [Related]
5. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of natural killer cell infiltration in hepatocellular carcinoma].
Zhu LY; Zhou J; Liu YZ; Pan WD
Ai Zheng; 2009 Nov; 28(11):1198-202. PubMed ID: 19895742
[TBL] [Abstract][Full Text] [Related]
7. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
8. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation.
Elinav E; Abd-Elnabi A; Pappo O; Bernstein I; Klein A; Engelhardt D; Rabbani E; Ilan Y
J Hepatol; 2006 Mar; 44(3):529-36. PubMed ID: 16310278
[TBL] [Abstract][Full Text] [Related]
9. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
10. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
[TBL] [Abstract][Full Text] [Related]
11. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
12. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
13. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis.
Yuan MM; Xu YY; Chen L; Li XY; Qin J; Shen Y
BMC Cancer; 2015 Apr; 15():245. PubMed ID: 25884709
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
15. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.
Fang L; Gong J; Wang Y; Liu R; Li Z; Wang Z; Zhang Y; Zhang C; Song C; Yang A; Ting JP; Jin B; Chen L
J Exp Clin Cancer Res; 2014 Sep; 33(1):76. PubMed ID: 25228093
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
17. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis.
Yoneda K; Sugimoto K; Shiraki K; Tanaka J; Beppu T; Fuke H; Yamamoto N; Masuya M; Horie R; Uchida K; Takei Y
Int J Oncol; 2008 Nov; 33(5):929-36. PubMed ID: 18949355
[TBL] [Abstract][Full Text] [Related]
18. High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice.
Qin WH; Yang ZS; Li M; Chen Y; Zhao XF; Qin YY; Song JQ; Wang BB; Yuan B; Cui XL; Shen F; He J; Bi YF; Ning G; Fu J; Wang HY
Gastroenterology; 2020 May; 158(6):1713-1727. PubMed ID: 31972238
[TBL] [Abstract][Full Text] [Related]
19. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
20. Head and neck cancer triggers the internalization of TLR3 in natural killer cells.
Xie L; Pries R; Kesselring R; Wulff S; Wollenberg B
Int J Mol Med; 2007 Oct; 20(4):493-9. PubMed ID: 17786279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
